Portfolio company
Rapidemic
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Rapidemic develops molecular point-of-care diagnostic tests for sexually transmitted infections, providing results for patients and clinicians without requiring laboratory infrastructure or external power.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Testmate Health
This company develops rapid urine-based diagnostic kits for individuals to test for sexually transmitted infections at home without requiring laboratory processing.
Videm
Videm develops a handheld diagnostic device for rapid molecular and protein detection of infectious diseases in care settings and at home.
Nanopath
This company develops point-of-care molecular diagnostic tests and hardware for pelvic and gynecologic infections to provide rapid results for healthcare providers and their patients.
Deepull
Deepull develops automated diagnostic systems that identify pathogens and antibiotic resistance directly from blood samples for healthcare providers treating sepsis and acute infections.
iFAST Diagnositcs
The company develops rapid antimicrobial susceptibility testing systems for hospitals and clinical laboratories to identify effective antibiotic treatments for bacterial infections.
Reme-D
This company develops molecular diagnostic kits for human and animal diseases to support healthcare providers and researchers in underserved regions.
AltraTech
AltraTech develops portable molecular diagnostic platforms for point-of-care testing of DNA, RNA, and antibodies for healthcare providers and the agrifood sector.
Septest
This company develops point-of-need blood tests for healthcare professionals to rapidly identify infection and inflammation biomarkers in patients.
